Jody. everyone for afternoon, us. and Good you, you Thank thank joining
highly therapy acids the January, small platform body's targeting sophisticated increasingly we outlook late non-toxic future of of call the we strategic believe genetic genetically-targeted on to proprietary is delivery on capitalizes During in our strategy lipid This molecules as extrahepatic LNC. and machinery our XXXX develop to nucleic detailed therapeutics the or our the focusing medicine. effective through technology, approaches of nanocrystal strategy
to genetic our world that our in a on putting are us believe business a material. to ever-evolving of and technology delivering strategy becoming LNC path leader continue We the
include liposomes, vectors. lipid delivery of options the for therapeutics viral nanoparticles available Currently intracellular and
While undesirable have challenging widely We LNC each delivery been our these that immunogenicity has extrahepatic such storage adopted, dangerous delivery, well-recognized and and formulations technologies adverse overcomes limitations of with limitations. many necessitate believe unstable these toxicity can conditions. as challenges platform and
significantly In are EnACT bolstered shorter-term the in is amphotericin able trial currently safe, outcomes. potent form in MATXXXX. a of confidence of platform brain deliver Results across blood-brain intravenous dramatic demonstrated LNC is with from the Phase by that a success B available of the clinical Our deadly fungal yet infection, oral II only our contrast available to barrier administration. the which antifungal well-tolerated toxic with formulations this to survival highly MATXXXX
companies internal Resilience, program acid exploring like larger world's oligonucleotides rapidly the messenger differentiating and leading RNA are key and during of actively National expected with development and X on to the being oligonucleotides smaller like platform are the space. DNA with for BioNTech siRNA with of collaborations working anticipated aspects and our notable of the these data working value-creating advance validate platform from readouts several second further milestones nucleic Among LNC quarter. ASOs emerging and in our We and
that recall RNA You April, research our technology and platform of collaboration we may announced a BioNTech involving BioNTech with combination exclusive formats. last LNC our messenger
and our of RNA, this to support, of to considered collaboration delivery large messenger oral potentially In capabilities the for provided holy the of technology RNA addition even meaningful financial delivered. to opportunity widely be delivery also an evaluate the grail has oligo
over in our in with vitro year testing. We expect vivo gain are of the extremely work progress to and upcoming past additional insights the pleased from
biological and complex in both one is can physiologic activity the of tissues delivery expression protein a achieving in The vivo protein results to vivo. impact intracellular transition success and expression factors in from in vitro many demonstration with of similar that subsequent
of we considered our licensing quickly decision our move in and oligonucleotides stage the therapeutic data potential expansion this will for applications set arising for from smaller the a collaboration believe of into BioNTech key us becomes to agreement. ultimately to point a vivo Importantly, both internal biodistribution collaboration larger and
of of One with delivery our technology administration. the is unique aspects of route flexibility its
messenger to highly as of pursuing as of the addition delivery technology RNA, challenging we to well also use systemic our for administration. evaluating routes other In oral are messenger the intramuscularly deliver RNA
demonstrated also deliver successful our a company space. technology field in that delivery extrahepatically delivery oligos liver, would of become to nucleic systemically large scientific acids with beyond can more the ability represent oral deliver the the a acid significant our of RNA advancement or is stable, also leader While a represent messenger toxic this and first, would the position to nucleic and less in
internal nucleic technology's the building advantages, property a view our solid cargo-dependent characteristics versatility intellectual We as we are a from both and We candidates product underlying believe external acid of and and potential in perspectives. our goal creating design pipeline space. of foundation
working our a us during current constraints exclusivity our and vivo work in year, many approach us RNA. month, vitro from both partners our The potential to as agreement in other BioNTech expire messenger the and compelling Things with BioNTech package. with past firms interest with we that next pursue collaboration allowing of over part internal to data position have of the learned
a delivery. in with area allowing broaden also expressed BioNTech to collaboration our with this of agreement the us discussions other benefit and engage leaders license our discussions, and in only interested who should We through while application the differentiated in have opportunity flexibility expanding interest in but those technology in this space remain
Moving Since certain that we delivery with closely comprehensive a January, have Resilience Resilience. on announcing and and on includes National research the Agreement been LNC in Material agreement optimization formulation, applying program working nucleic Evaluation and to acids platform. this design, Transfer our of
XXXX. could technologies, space. true bringing second envision expertise, partner during in anticipate quarter to a in relationships the We and of for with data unparalleled nucleic National available collaborative our manufacturing then our half advancing testing Resilience CMC We in with second platform potentially work the testing scale vitro that industry vivo data the in be acid
for also results such our from of the oligos, we ASOs program internal oligonucleotides the coming and or siRNAs. smaller or anticipate months, RNA as antisense In interfering short delivery
chosen of greater to internal the smaller delivery and vitro on vivo of with our have encapsulated, because ease in which and studies molecules. successful platform technology focus oligos the overall prior can oral they be of the with in in We smaller efforts these LNC documented success delivery their in our
cargoes, we in later this next internal company's studies the animal highly positioning a candidate and and Matinas intend XXXX. and in initial vitro in testing of Following be developing multiple product vivo half to expected of newer These pipeline identifying in siRNA are in agents, useful including biodistribution broader efficacy the with with therapeutic therapies. forward move to ASO year data for second
potential the serious like fungal lost validated development I'd enthusiasm fact potential lives to acid asset sight MATXXXX, that have clinical of we agent deadly program. in infections. of ideal to for the now MATXXXX all turn to the potentially next saves for technology drug steps a With and treatment become invasive have nucleic antifungal in for our and key of clinically the our applications in not a we that space, the has the
for the meeting a place that take type scheduled underway is second with FDA in to B are quarter. Preparations the
and III and on are trial infections clinical MATXXXX in of safety life-threatening guidance there with agency's the invasive fungal which the Phase seeking of the a be for treatment agreement options. design efficacy, to assess oral tolerability patients will few We
marketing design MATXXXX overall approval for will pivotal of proposed strategy for multitude include a achieving infection study meeting The and discussion invasive fungal of indications. our a treatment
prudent makes funds decision in broader partners. targeted the plans cryptococcal to to the indications complete BARDA support these Such be Phase potentially development the the infections well through funding nondilutive for gain announced, meningitis. MATXXXX and supply FDA receive believe commercial As Phase asset market to more on feedback to fungal going as this prior as from study and in and/or readiness. We made III approval previously attractive for to IFI on Matinas a from we infections invasive to our positions potential into sufficient fungal much a focus chain important could of NIH III invasive
oral, strong treatments. trial profile, cryptococcal in upon criteria broad-spectrum MATXXXX is in set funding promising and believe We BARDA its recent Phase forth antifungal the EnACT the success and a II for candidate clinical meningitis based its grants for by well-tolerated for BARDA
drug pursuing XX believe IFIs opportunity. potential, commercial means provides significant also the of years expansion, U.S. additional important and need global there to and We commercial where for the for maximize MATXXXX's favorably potential this and best with position in the will also is exclusivity domestically
XXXX to review Now, financial the I'd to over Kucinski like performance. to Keith call our Keith? turn
